Out of the 80 ROIs, Aiforia over-counted the number of Ki67 positive tumor cells in 51% (41/80), under-counted in 6% (5/80), and got matching results in 43% (34/80), whereas ImageScope over-counted in 70% (56/80) and obtained matching results with the reference standard in 30% (24/80) of the ROIs (Supplementary Table S4). Here, MKI67 is linked to neoplasm.